Schering K-Dur Settlement With AHP Under Investigation By FTC
Executive Summary
A settlement between Schering-Plough and ESI Lederle regarding patent litigation surrounding Schering's K-Dur is among cases being investigated by the Federal Trade Commission for potential antitrust violations.
You may also be interested in...
FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First
Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.
FTC K-Dur Suit Would Allow Andrx Generic Launch; FDA Could Act First
Andrx believes it may be able to launch a generic version of Schering-Plough's K-Dur during the second half of the year regardless of the outcome of the Federal Trade Commission's administrative action over patent settlements involving K-Dur.
K-Dur generic
Schering has settled patent litigation regarding generic potassium chloride with Upsher-Smith, the company reports in its Nov. 13 10-Q. Schering also settled with ESI Lederle; the agreements are under FTC investigation (1"The Pink Sheet" April 3, p. 6)